Dey Asim B, Khedr Sherif, Bean James, Porras Leah L, Meredith Tamika D, Willard Francis S, Hass Joseph V, Zhou Xin, Terashvili Maia, Jesudason Cynthia D, Ruley Kevin M, Wiley Michael R, Kowala Mark, Atkinson Simon J, Staruschenko Alexander, Rekhter Mark D
Eli Lilly and Company, Indianapolis, IN, United States.
Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, United States.
Front Physiol. 2020 Sep 8;11:543727. doi: 10.3389/fphys.2020.543727. eCollection 2020.
Regulation of the peripheral vascular resistance via modulating the vessel diameter has been considered as a main determinant of the arterial blood pressure. Phosphodiesterase enzymes (PDE1-11) hydrolyse cyclic nucleotides, which are key players controlling the vessel diameter and, thus, peripheral resistance. Here, we have tested and reported the effects of a novel selective PDE1 inhibitor (BTTQ) on the cardiovascular system. Normal Sprague Dawley, spontaneously hypertensive (SHR), and Dahl salt-sensitive rats were used to test the efficacy of the compound. Phosphodiesterase radiometric enzyme assay revealed that BTTQ inhibited all three isoforms of PDE1 in nanomolar concentration, while micromolar concentrations were needed to induce effective inhibition for other PDEs. The myography study conducted on mesenteric arteries revealed a potent vasodilatory effect of the drug, which was confirmed by an increase in the blood flow in the rat ear arteriols reflected by the rise in the temperature. Furthermore, BTTQ proved a high efficacy in lowering the blood pressure about 9, 36, and 24 mmHg in normal Sprague Dawley, SHR and, Dahl salt-sensitive rats, respectively, compared to the vehicle-treated group. Moreover, additional blood pressure lowering of about 22 mmHg could be achieved when BTTQ was administered on top of ACE inhibitor lisinopril, a current standard of care in the treatment of hypertension. Therefore, PDE1 inhibition induced efficient vasodilation that was accompanied by a significant reduction of blood pressure in different hypertensive rat models. Administration of BTTQ was also associated with increased heart rate in both models of hypertension as well as in the normotensive rats. Thus, PDE1 appears to be an attractive therapeutic target for the treatment of resistant hypertension, while tachycardia needs to be addressed by further compound structural optimization.
通过调节血管直径来调节外周血管阻力被认为是动脉血压的主要决定因素。磷酸二酯酶(PDE1 - 11)可水解环核苷酸,而环核苷酸是控制血管直径进而控制外周阻力的关键因素。在此,我们测试并报告了一种新型选择性PDE1抑制剂(BTTQ)对心血管系统的影响。使用正常的斯普拉格 - 道利大鼠、自发性高血压大鼠(SHR)和达尔盐敏感大鼠来测试该化合物的疗效。磷酸二酯酶放射酶分析法显示,BTTQ在纳摩尔浓度下可抑制PDE1的所有三种亚型,而对其他磷酸二酯酶则需要微摩尔浓度才能诱导有效抑制。对肠系膜动脉进行的肌动描记术研究显示该药物具有强大的血管舒张作用,大鼠耳小动脉血流增加所反映的温度升高证实了这一点。此外,与载体处理组相比,BTTQ在正常斯普拉格 - 道利大鼠、SHR大鼠和达尔盐敏感大鼠中分别显示出高效的降压效果,血压分别降低约9、36和24 mmHg。此外,当在当前高血压治疗的标准护理药物血管紧张素转换酶抑制剂赖诺普利基础上加用BTTQ时,可进一步降低血压约22 mmHg。因此,抑制PDE1可诱导有效的血管舒张,并伴随不同高血压大鼠模型的血压显著降低。在高血压模型和正常血压大鼠中,给予BTTQ还会导致心率增加。因此,PDE1似乎是治疗顽固性高血压的一个有吸引力的治疗靶点,而心动过速问题需要通过进一步优化化合物结构来解决。